| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8b958e312aa267aa4fd69d36cceb869d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d21949c0f2d752717918db645b47c884
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_edde9367c203ecf6f83b62472b802c9b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_985bb4dc9ca6c08a8752cb23d34991e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96989b65b9fb0dda21e57ca5baf6b9e3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y10S514-814 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0021
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0061 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 |
| filingDate |
2009-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45fad5eccabde56e9725945504043cd5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a42091d53023e017a382830ce34348f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e963cc587ed30331cda3418b0a99be94 |
| publicationDate |
2015-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8999296-B2 |
| titleOfInvention |
Method of detecting bladder cancer |
| abstract |
Provided is a sensitizing detection agent of an oral or intravenous administration type which enables the detection of bladder cancer with a higher sensitivity without causing pain to the patient. A sensitizing detection agent for bladder cancer comprising 5-aminolevulinic acid (ALA), a derivative thereof, or a salt of these is orally or intravenously administered, and a video camera system is inserted via the urethra and a blue light at 380-440 nm is irradiated to observe the red fluorescent part. Further, VLD-M1 is inserted and a blue light at 405 nm is irradiated to observe fluorescence intensity (relative intensity) of the red light part. For oral administration, 20 mg/kg (maximum of 1 g) of ALA is dissolved in 50 mL of a 5% glucose solution prior to the administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014188034-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9550073-B2 |
| priorityDate |
2008-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |